Taken together, our results support the idea that mutant CBL‐expressing AML, characterized by hyperactivation of FLT3 signalling, is susceptible to killing by similar approaches used for mutant FLT3‐positive AML. The gene discussed is FLT3; the disease is acute myeloid leukemia.